Wall Street analysts predict that La Jolla Pharmaceutical (NASDAQ:LJPC) will report earnings per share (EPS) of ($1.25) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for La Jolla Pharmaceutical’s earnings. The highest EPS estimate is ($1.10) and the lowest is ($1.38). La Jolla Pharmaceutical posted earnings of ($1.44) per share during the same quarter last year, which suggests a positive year over year growth rate of 13.2%. The company is expected to announce its next quarterly earnings results on Thursday, February 22nd.
On average, analysts expect that La Jolla Pharmaceutical will report full-year earnings of ($4.91) per share for the current financial year, with EPS estimates ranging from ($5.05) to ($4.74). For the next financial year, analysts forecast that the business will post earnings of ($4.46) per share, with EPS estimates ranging from ($5.45) to ($3.10). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow La Jolla Pharmaceutical.
A number of brokerages have recently issued reports on LJPC. BidaskClub lowered La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Thursday. Zacks Investment Research lowered La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Thursday. ValuEngine raised La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Jefferies Group lowered La Jolla Pharmaceutical from a “buy” rating to an “underperform” rating and dropped their target price for the stock from $40.00 to $29.00 in a research report on Monday, February 12th. Finally, HC Wainwright began coverage on La Jolla Pharmaceutical in a research report on Thursday, December 21st. They set a “buy” rating and a $62.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $57.00.
Shares of La Jolla Pharmaceutical (LJPC) traded up $0.91 on Monday, hitting $33.87. The company’s stock had a trading volume of 452,090 shares, compared to its average volume of 508,692. The firm has a market capitalization of $750.06, a PE ratio of -6.64 and a beta of 1.20. La Jolla Pharmaceutical has a 12 month low of $16.71 and a 12 month high of $41.36.
In other La Jolla Pharmaceutical news, COO Jennifer Carver bought 1,000 shares of the company’s stock in a transaction dated Wednesday, December 27th. The shares were acquired at an average cost of $33.22 per share, with a total value of $33,220.00. Following the completion of the transaction, the chief operating officer now owns 4,500 shares in the company, valued at $149,490. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Life Sciences Maste Perceptive bought 175,000 shares of the company’s stock in a transaction dated Wednesday, February 14th. The shares were acquired at an average cost of $32.72 per share, for a total transaction of $5,726,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 177,000 shares of company stock worth $5,792,440. Corporate insiders own 25.47% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. MetLife Investment Advisors LLC bought a new stake in La Jolla Pharmaceutical in the fourth quarter valued at about $276,000. LPL Financial LLC bought a new stake in La Jolla Pharmaceutical in the fourth quarter valued at about $434,000. Perceptive Advisors LLC increased its holdings in La Jolla Pharmaceutical by 57.1% in the fourth quarter. Perceptive Advisors LLC now owns 3,388,611 shares of the biopharmaceutical company’s stock valued at $109,046,000 after buying an additional 1,231,600 shares during the last quarter. Jafra Capital Management LP increased its holdings in La Jolla Pharmaceutical by 238.5% in the fourth quarter. Jafra Capital Management LP now owns 30,000 shares of the biopharmaceutical company’s stock valued at $965,000 after buying an additional 21,137 shares during the last quarter. Finally, Consonance Capital Management LP increased its holdings in La Jolla Pharmaceutical by 3.8% in the fourth quarter. Consonance Capital Management LP now owns 2,079,311 shares of the biopharmaceutical company’s stock valued at $66,912,000 after buying an additional 76,792 shares during the last quarter.
TRADEMARK VIOLATION WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/19/zacks-brokerages-expect-la-jolla-pharmaceutical-ljpc-to-announce-1-25-eps.html.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Get a free copy of the Zacks research report on La Jolla Pharmaceutical (LJPC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.